Boai NKY Medical Holdings Ltd.
新开源
300109
Shenzhen Stock Exchange
Company Profile
1.Products quality We are the first Chinese high-tech specialty chemical company focused on the development and manufacture of PVP series products, Our current product series include: GBL, 2-pyrrolidone, NVP monomer, PVP K series(Povidone), Copovidone, PVPP (Crospovidone), PVP-Iodine(Povidone-Iodine), Vinyl Ether intermediates and PVM/MA copolymers. We are the only Chinese manufacturer capable of offering PVP K12 (powder and liquid), PVP K90 powder, PVP K60 powder, PVP K120 powder, PVM/MA copolymer and high purity Vinyl Ether intermediates. Aside from domestic market, our products are exported to Europe, US, Japan, Australia, Latin America and other foreign countries. 2.R&D ability NKY has been focused on the innovation of our production process and the development of new products, we have founded a well-equipped R&D center in our manufacture plant as well as a Polymer applications Research Center in Tianjin. 3.Potential in new market Precision medical service is an extremely new market in China, the potential in this area is tremendous, and Chinese government supports its development. Besides the aforementioned, NKY also has advantages in Market Occupation, Intellectual Properties and Human Resource comparing to other companies.
Full description
Boai NKY Pharmaceuticals Ltd’s key business comprises fine chemicals and precision medical services. The fine chemicals business area offers products such as PVP series products , PVM/MA copolymer series products, and oral-care related series products. In addition, precision medical services area covers pre-cancerous screening, which is based on gene sequencing as the main technology platform, molecular diagnosis of women's disease, personalized medical treatment, etc.. NKY is the first Chinese high-tech specialty chemical company focused on the development and manufacture of PVP series products. Its manufacture plant covers an area of 138,000 square meters (floor area 56,000 square meters). All the production of our pharmaceutical/ cosmetics/ food/ oral-care series products comply with cGMP, which makes NKY an industry model in China. The results of our independent research and development have filled industry blank in China: we have obtained 16 patents of invention, 21 patents of utility model, 20 Certificates for Computer Software Copyright, 16 know-hows, many of them reach national or international advanced level. In terms of branding, we also registered 33 trademarks. In recent years, NKY is the biggest supplier of PVP products in China, the 3rd largest globally. NKY is regarded as a pioneering corporation in China’s precision medical service sector. The company currently owns a number of medical patents and other intellectual property rights, for instance, the SPICM-DNA Automatic Cell screening Analysis System developed by NKY’s daughter company, Heer Medical, fills the domestic gap to a great extent. Over the last decade, a powerful database has been gradually built up with the accumulated data of more than one million people. Specifically, NKY’s another daughter company, 3G Biotech, is the leading firm in the field of Chinese pharmacogenomics. Its laboratory has already received excellent grades for four consecutive years in the relevant EQA (External Quality Assesment) held by National Health and Family Planning Commission. In 2016, 3G Biotech cooperating with Peking University undertook the National Key R&D Plan titled “Comprehensive Evaluation System for Chinese pharmacogenomics and Chinese People’s Precision Medicine”, it means NKY will be a participator involved in the formulation of the national standard for precision medicine. Furthermore, Genergy Bio-Technology (NKY’s third daughter company) has the most advanced high throughput sequencing, gene chip, Bioinformatics and molecular biology technology platform, and it has been awarded as the Illumina CSPro and also BioNano CsPro Official Certified Service Provider for many years. The company has successfully completed more than 2000 scientific research service projects, assisted the clients in publishing about 90 articles which equal approximately 700 Impact Factors.